These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

165 related items for PubMed ID: 34908832

  • 1. Factors Associated with Reduction of Sedentary Time Following Tiotropium/Olodaterol Therapy in Treatment-Naïve Chronic Obstructive Pulmonary Disease.
    Takahashi K, Tashiro H, Tajiri R, Takamori A, Uchida M, Kato G, Kurihara Y, Sadamatsu H, Kinoshita T, Yoshida M, Kawaguchi A, Kimura S, Sueoka-Aragane N, Kawayama T, Saga-naïve COPD Physical Activity Evaluation (SCOPE) Study Investigator Group.
    Int J Chron Obstruct Pulmon Dis; 2021; 16():3297-3307. PubMed ID: 34908832
    [Abstract] [Full Text] [Related]

  • 2. First-Line Treatment with Tiotropium/Olodaterol Improves Physical Activity in Patients with Treatment-Naïve Chronic Obstructive Pulmonary Disease.
    Takahashi K, Uchida M, Kato G, Takamori A, Kinoshita T, Yoshida M, Tajiri R, Kojima K, Inoue H, Kobayashi H, Sadamatsu H, Tashiro H, Tanaka M, Hayashi S, Kawaguchi A, Kimura S, Sueoka-Aragane N, Kawayama T, Saga-naïve COPD Physical Activity Evaluation (SCOPE) Study Investigator Group.
    Int J Chron Obstruct Pulmon Dis; 2020; 15():2115-2126. PubMed ID: 32982204
    [Abstract] [Full Text] [Related]

  • 3. Efficacy of tiotropium/olodaterol on lung volume, exercise capacity, and physical activity.
    Ichinose M, Minakata Y, Motegi T, Ueki J, Gon Y, Seki T, Anzai T, Nakamura S, Hirata K.
    Int J Chron Obstruct Pulmon Dis; 2018; 13():1407-1419. PubMed ID: 29750027
    [Abstract] [Full Text] [Related]

  • 4. Efficacy of Tiotropium/Olodaterol Compared with Tiotropium as a First-Line Maintenance Treatment in Patients with COPD Who Are Naïve to LAMA, LABA and ICS: Pooled Analysis of Four Clinical Trials.
    Buhl R, de la Hoz A, Xue W, Singh D, Ferguson GT.
    Adv Ther; 2020 Oct; 37(10):4175-4189. PubMed ID: 32671684
    [Abstract] [Full Text] [Related]

  • 5. Effectiveness of Tiotropium/Olodaterol in the Real World: A Post Hoc Subgroup Analysis After the First Year of Use.
    Sato A, Miyazaki A, Nakamura S.
    Adv Ther; 2022 Oct; 39(10):4692-4706. PubMed ID: 35948844
    [Abstract] [Full Text] [Related]

  • 6. Assessment of physical functioning and handling of tiotropium/olodaterol Respimat® in patients with COPD in a real-world clinical setting.
    Steinmetz KO, Abenhardt B, Pabst S, Hänsel M, Kondla A, Bayer V, Buhl R.
    Int J Chron Obstruct Pulmon Dis; 2019 Oct; 14():1441-1453. PubMed ID: 31308649
    [Abstract] [Full Text] [Related]

  • 7. Efficacy of tiotropium and olodaterol combination therapy on dynamic lung hyperinflation evaluated by hyperventilation in COPD: an open-label, comparative before and after treatment study.
    Kawachi S, Fujimoto K.
    Int J Chron Obstruct Pulmon Dis; 2019 Oct; 14():1167-1176. PubMed ID: 31213796
    [Abstract] [Full Text] [Related]

  • 8. Effects of tiotropium + olodaterol versus tiotropium or placebo by COPD disease severity and previous treatment history in the OTEMTO® studies.
    Singh D, Gaga M, Schmidt O, Bjermer L, Grönke L, Voß F, Ferguson GT.
    Respir Res; 2016 Jun 18; 17(1):73. PubMed ID: 27316465
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of tiotropium and olodaterol in COPD: a systematic review and meta-analysis.
    Miravitlles M, Urrutia G, Mathioudakis AG, Ancochea J.
    Respir Res; 2017 Nov 25; 18(1):196. PubMed ID: 29178871
    [Abstract] [Full Text] [Related]

  • 10. Pharmacokinetics and safety of tiotropium+olodaterol 5 μg/5 μg fixed-dose combination in Chinese patients with COPD.
    Wang Z, Tadayasu Y, Hu N, Shu S, Hu C, Luo Z.
    Pulm Pharmacol Ther; 2020 Aug 25; 63():101944. PubMed ID: 32916296
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and safety of tiotropium + olodaterol maintenance treatment in patients with COPD in the TONADO® and OTEMTO® studies: a subgroup analysis by age.
    Ferguson GT, Karpel JP, Clerisme-Beaty E, Grönke L, Voß F, Buhl R.
    Int J Chron Obstruct Pulmon Dis; 2016 Aug 25; 11():2701-2710. PubMed ID: 27843306
    [Abstract] [Full Text] [Related]

  • 12. Effects of baseline symptom burden on treatment response in COPD.
    Martinez FJ, Abrahams RA, Ferguson GT, Bjermer L, Grönke L, Voß F, Singh D.
    Int J Chron Obstruct Pulmon Dis; 2019 Aug 25; 14():181-194. PubMed ID: 30655665
    [Abstract] [Full Text] [Related]

  • 13. Tiotropium/Olodaterol Delays Clinically Important Deterioration Compared with Tiotropium Monotherapy in Patients with Early COPD: a Post Hoc Analysis of the TONADO® Trials.
    Rabe KF, Chalmers JD, Miravitlles M, Kocks JWH, Tsiligianni I, de la Hoz A, Xue W, Singh D, Ferguson GT, Wedzicha J.
    Adv Ther; 2021 Jan 25; 38(1):579-593. PubMed ID: 33175291
    [Abstract] [Full Text] [Related]

  • 14. Lung function and long-term safety of tiotropium/olodaterol in East Asian patients with chronic obstructive pulmonary disease.
    Bai C, Ichinose M, Lee SH, Lee KH, Jöns O, Bothner U, Zhao Y, Buhl R.
    Int J Chron Obstruct Pulmon Dis; 2017 Jan 25; 12():3329-3339. PubMed ID: 29200840
    [Abstract] [Full Text] [Related]

  • 15. Effect of tiotropium/olodaterol on sedentary and active time in patients with COPD: post hoc analysis of the VESUTO® study.
    Minakata Y, Motegi T, Ueki J, Gon Y, Nakamura S, Anzai T, Hirata K, Ichinose M.
    Int J Chron Obstruct Pulmon Dis; 2019 Jan 25; 14():1789-1801. PubMed ID: 31496678
    [Abstract] [Full Text] [Related]

  • 16. Impact of tiotropium + olodaterol on physical functioning in COPD: results of an open-label observational study.
    Sauer R, Hänsel M, Buhl R, Rubin RA, Frey M, Glaab T.
    Int J Chron Obstruct Pulmon Dis; 2016 Jan 25; 11():891-8. PubMed ID: 27217742
    [Abstract] [Full Text] [Related]

  • 17. Combined bronchodilators (tiotropium plus olodaterol) for patients with chronic obstructive pulmonary disease.
    Ramadan WH, Kabbara WK, El Khoury GM, Al Assir SA.
    Int J Chron Obstruct Pulmon Dis; 2015 Jan 25; 10():2347-56. PubMed ID: 26586940
    [Abstract] [Full Text] [Related]

  • 18. Effect of 12 weeks of once-daily tiotropium/olodaterol on exercise endurance during constant work-rate cycling and endurance shuttle walking in chronic obstructive pulmonary disease.
    Maltais F, O'Donnell D, Gáldiz Iturri JB, Kirsten AM, Singh D, Hamilton A, Tetzlaff K, Zhao Y, Casaburi R.
    Ther Adv Respir Dis; 2018 Jan 25; 12():1753465818755091. PubMed ID: 29439648
    [Abstract] [Full Text] [Related]

  • 19. Benefits of Tiotropium/Olodaterol Compared with Tiotropium in Patients with COPD Receiving only LAMA at Baseline: Pooled Analysis of the TONADO® and OTEMTO® Studies.
    Buhl R, Singh D, de la Hoz A, Xue W, Ferguson GT.
    Adv Ther; 2020 Aug 25; 37(8):3485-3499. PubMed ID: 32462607
    [Abstract] [Full Text] [Related]

  • 20. Study Design of VESUTO®: Efficacy of Tiotropium/Olodaterol on Lung Hyperinflation, Exercise Capacity, and Physical Activity in Japanese Patients with Chronic Obstructive Pulmonary Disease.
    Ichinose M, Minakata Y, Motegi T, Ueki J, Seki T, Anzai T, Takizawa A, Grönke L, Hirata K.
    Adv Ther; 2017 Jul 25; 34(7):1622-1635. PubMed ID: 28537001
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.